

Tokyo Metropolitan Bokutoh General Hospital, Sumida-Ku, Tokyo, Japan (I Kubo); Division of Cardiology, Omura Municipal Hospital, Omura, Nagasaki, Japan (Y Tanioka); Department of Cardiology, National Hospital Organisation Mito Medical Centre, Higashi Ibaraki-gun, Ibaraki, Japan (S Taguchi); Department of Cardiology, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan (A Yamashina); Department of Cardiology, Fukuyama City Hospital, Fukuyama, Hiroshima, Japan (K Hashimoto); Department of Medicine, Nippon Medical School Chiba Hokuso Hospital, Inba-Gun, Chiba, Japan (K Mizuno); Department of Cardiology, Kanazawa Medical University, Kahoku-Gun, Ishikawa, Japan (S Okubo); Department of Internal Medicine, University of Yamanashi Faculty of Medicine, Chuo, Yamanashi, Japan (K Kugiyama); Department of Cardiology, Tsukazaki Memorial Hospital, Himeji, Hyogo, Japan (H Iida); Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Chiba, Japan (I Komuro); Department of Cardiovascular Medicine, Graduate School of Medical Sciences Kumamoto University, Kumamoto, Kumamoto, Japan (H Ogawa); Department of Cardiology, Shizuoka Prefectural General Hospital, Shizuoka, Shizuoka, Japan (O Doi); Division of Cardiology, Tokyo Metropolitan Geriatric Hospital, Itabashi-Ku, Tokyo, Japan (K Harada); Department of Internal Medicine, Cardiovascular Division, Asahikawa Medical College, Asahikawa, Hokkaido, Japan (N Hasebe); Department of Cardiology, Sasebo City General Hospital, Sasebo, Nagasaki, Japan (T Yamasa); Department of Internal Medicine, Division of Coronary Heart Disease, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan (M Masutani); Department of Cardiovascular Medicine, Graduate School of Medical Sciences Kyushu University, Fukuoka, Fukuoka, Japan (K Egashira); Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Bunkyo-Ku, Tokyo, Japan (M Isobe); Department of Internal Medicine and Cardiology, Graduate School of Medicine Osaka City University, Osaka, Osaka, Japan (M Yoshiyama); Department of Cardiology, Tokyo Women's Medical University, Shinjuku-Ku, Tokyo, Japan (H Kasanuki); Department of Cardiology, Nagasaki Citizens Hospital, Nagasaki, Nagasaki, Japan (S Suzuki); Department of Emergency and Critical Care Medicine, Chikushi Hospital Fukuoka University, Chikushino, Fukuoka, Japan (H Mihara).

Conflict of interest statement

We declare that we have no conflict of interest.

Acknowledgments

These studies were supported by grants for Comprehensive Research on Ageing and Health (H13-21seiki (seikatsu) 23), in Health and Labour Sciences Research from Ministry of Health, Labour and Welfare, Japan, and by a grant from the Japanese Cardiovascular Research Foundation. We thank Satomi Ihara for her excellent assistance with data management; Hidetoshi Okazaki, Hiroyuki Yamamoto, Masakatsu Wakeno, Atsushi Nakano, Hiroyuki Takahama, Shin Ito, Hideyuki Sasaki, and Kyungduk Min for analysis of angiographs of left ventricles; Yoshie Yanagi, Hiromi Ohara, Chikayo Tsujimoto, Naoko Matsuo, Yoshihiro Asano, Masashi Fujita, Shuichiro Higo, and Mitsutoshi Asai for data monitoring; Ms Uchida at SACT international for data analysis; Dr Tsutomu Yamazaki for data management; and Dr Ed Schweitzer for review of the manuscript.

References

- Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics—2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. *Circulation* 2006; 113: 85–151.
- Jessup M, Brozena S. Heart failure. *N Engl J Med* 2003; 348: 2007–18.
- Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. *N Engl J Med* 2002; 347: 1397–402.
- Shiba N, Watanabe J, Shinozaki T, et al. Poor prognosis of Japanese patients with chronic heart failure following myocardial infarction—comparison with nonischemic cardiomyopathy. *Circ J* 2005; 69: 143–49.
- Kloner RA, Rezkalla SH. Cardiac protection during acute myocardial infarction: where do we stand in 2004? *J Am Coll Cardiol* 2004; 44: 276–86.
- The MIAMI Trial Research Group. Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial. *Eur Heart J* 1985; 6: 199–226.
- Ross AM, Gibbons RJ, Stone GW, Kloner RA, Alexander RW. A randomised, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). *J Am Coll Cardiol* 2005; 45: 1775–80.
- van der Horst IC, Zijlstra F, van't Hof AW, et al. Glucose-insulin-potassium infusion inpatients treated with primary angioplasty for acute myocardial infarction: the glucose-insulin-potassium study: a randomised trial. *J Am Coll Cardiol* 2003; 42: 784–91.
- Grines CL, Browne KF, Marco J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group. *N Engl J Med* 1993; 328: 673–79.
- Sakurai K, Watanabe J, Iwabuchi K, et al. Comparison of the efficacy of reperfusion therapies for early mortality from acute myocardial infarction in Japan: registry of Miyagi Study Group for AMI (MsAMI). *Circ J* 2003; 67: 209–14.
- Lamas GA, Flaker GC, Mitchell G, et al. Effect of infarct artery patency on prognosis after acute myocardial infarction. The Survival and Ventricular Enlargement Investigators. *Circulation* 1995; 92: 1101–09.
- Verma S, Fedak PW, Weisel RD, et al. Fundamentals of reperfusion injury for the clinical cardiologist. *Circulation* 2002; 105: 2332–36.
- Zeyner U, Suryapranata H, Monassier JP, et al. The Na(+)/H(+) exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (ESCAMI) trial. *J Am Coll Cardiol* 2001; 38: 1644–50.
- European Study of Prevention of Infarct with Molsidomine (ESPRIM) Group. The ESPRIM trial: short-term treatment of acute myocardial infarction with molsidomine. *Lancet* 1994; 344: 91–97.
- Wall TC, Califf RM, Blankenship J, et al. Intravenous fluosol in the treatment of acute myocardial infarction. Results of the Thrombolysis and Angioplasty in Myocardial Infarction 9 Trial. TAMI 9 Research Group. *Circulation* 1994; 90: 114–20.
- Cody RJ, Atlas SA, Laragh JH, et al. Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. *J Clin Invest* 1986; 78: 1362–74.
- Emori T, Hirata Y, Imai T, Eguchi S, Kanno K, Marumo F. Cellular mechanism of natriuretic peptides-induced inhibition of endothelin-1 biosynthesis in rat endothelial cells. *Endocrinology* 1993; 133: 2474–80.
- Kitakaze M, Minamino T, Node K, et al. Role of activation of ectosolic 5'-nucleotidase in the cardioprotection mediated by opening of K⁺ channels. *Am J Physiol* 1996; 270: 1744–56.
- Mizumura T, Nithipatikom K, Gross GJ. Infarct size-reducing effect of nicorandil is mediated by the KATP channel but not by its nitrate-like properties in dogs. *Cardiovasc Res* 1996; 32: 274–85.
- Hayashi M, Tsutamoto T, Wada A, et al. Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction. *J Am Coll Cardiol* 2001; 37: 1820–26.
- Kuga H, Ogawa K, Oida A, et al. Administration of atrial natriuretic peptide attenuates reperfusion phenomena and preserves left ventricular regional wall motion after direct coronary angioplasty for acute myocardial infarction. *Circ J* 2003; 67: 443–48.
- Sugimoto K, Ito H, Iwakura K, et al. Intravenous nicorandil in conjunction with coronary reperfusion therapy is associated with better clinical and functional outcomes in patients with acute myocardial infarction. *Circ J* 2003; 67: 295–300.
- Sakata Y, Kodama K, Komamura K, et al. Salutary effect of adjunctive intracoronary nicorandil administration on restoration of myocardial blood flow and functional improvement in patients with acute myocardial infarction. *Am Heart J* 1997; 133: 616–21.
- Fukuzawa S, Ozawa S, Inagaki M, et al. Nicorandil affords cardioprotection in patients with acute myocardial infarction treated with primary percutaneous transluminal coronary angioplasty: assessment with thallium-201/iodine-123 BMIPP dual SPECT. *J Nucl Cardiol* 2000; 7: 447–53.

- 25 Ishii H, Ichimiya S, Kanashiro M, et al. Impact of a single intravenous administration of nicorandil before reperfusion in patients with ST-segment-elevation myocardial infarction. *Circulation* 2005; 112: 1284–88.
- 26 Asakura M, Jiyoong K, Minamino T, Shintani Y, Asanuma H, Kitakaze M. Rationale and design of a large-scale trial using atrial natriuretic peptide (ANP) as an adjunct to percutaneous coronary intervention for ST-segment elevation acute myocardial infarction: Japan-Working groups of acute myocardial infarction for the reduction of Necrotic Damage by ANP (J-WIND-ANP). *Circ J* 2004; 68: 95–100.
- 27 Minamino T, Jiyoong K, Asakura M, Shintani Y, Asanuma H, Kitakaze M. Rationale and design of a large-scale trial using nicorandil as an adjunct to percutaneous coronary intervention for ST-segment elevation acute myocardial infarction: Japan-Working groups of acute myocardial infarction for the reduction of Necrotic Damage by a K-ATP channel opener (J-WIND-KATP). *Circ J* 2004; 68: 101–06.
- 28 Seino Y, Tomita Y, Hoshino K, Setsuta K, Takano T, Hayakawa H. Pathophysiological analysis of serum troponin T release kinetics in evolving ischemic myocardial injury. *Jpn Circ J* 1996; 60: 265–76.
- 29 Steen H, Giannitsis E, Futterer S, Merten C, Juenger C, Katus HA. Cardiac troponin T at 96 hours after acute myocardial infarction correlates with infarct size and cardiac function. *J Am Coll Cardiol* 2006; 48: 2192–94.
- 30 Vollmer RT, Christenson RH, Reimer K, Ohman EM. Temporal creatine kinase curves in acute myocardial infarction. Implications of a good empirical fit with the log-normal function. *Am J Clin Pathol* 1993; 100: 293–98.
- 31 Therneau TM, Grambsch PM. Modeling survival data: extending the Cox model. New York, USA: Springer, 2000.
- 32 Hess KR. Graphical methods for assessing violations of the proportional hazards assumption in Cox regression. *Stat Med* 1995; 14: 1707–23.
- 33 Mahaffey KW, Puma JA, Barbagelata NA, et al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomised, placebo-controlled trial: the Acute Myocardial Infarction Study of Adenosine (AMISTAD) trial. *J Am Coll Cardiol* 1999; 34: 1711–20.
- 34 Grover GJ, Sleph PG, Dzwonczyk S. Role of myocardial ATP-sensitive potassium channels in mediating preconditioning in the dog heart and their possible interaction with adenosine A1-receptors. *Circulation* 1992; 86: 1310–16.
- 35 IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. *Lancet* 2002; 359: 1269–75.

Original Article

Association of Genetic Polymorphisms of Endothelin-Converting Enzyme-1 Gene with Hypertension in a Japanese Population and Rare Missense Mutation in Preproendothelin-1 in Japanese Hypertensives

Mariko BANNO^{1),2)}, Hironori HANADA¹⁾, Kei KAMIDE³⁾, Yoshihiro KOKUBO⁴⁾, Akiko KADA¹⁾, Jin YANG^{1),3)}, Chihiro TANAKA¹⁾, Shin TAKIUCHI³⁾, Takeshi HORIO³⁾, Tetsutaro MATAYOSHI³⁾, Hisayo YASUDA³⁾, Junko NAGURA⁴⁾, Hitonobu TOMOIKE⁴⁾, Yuhei KAWANO³⁾, and Toshiyuki MIYATA¹⁾

Endothelin-1 (EDN1), a 21-amino acid peptide, is a potent vasoconstrictor with various pharmacological responses. EDN1 is synthesized from a 212-amino acid precursor protein, preproEDN1, through multiple proteolytic steps. Endothelin-converting enzyme (ECE) cleaves a Trp73–Val74 peptide bond in big-EDN1 to give rise to mature EDN1. In this study, we examined the possible association of genetic variations in *ECE1* with hypertension in a general Japanese population and searched for missense mutations in and around the EDN1 polypeptide. We genotyped 5 single nucleotide polymorphisms (SNPs) in the *ECE1* gene in 1,873 individuals from a general Japanese population and identified one SNP associated with hypertension in women (rs212528: TT vs. TC+CC: odds ratio=1.40; 95% confidence intervals: 1.04–1.89; $p=0.026$), after adjusting for confounding factors. The systolic blood pressure in women with the CC genotype was 6.44 mmHg higher than that in those with the TT genotype ($p=0.007$), after adjusting for the same factors. Next, to identify the missense mutations that may influence the biological activity of EDN1, we sequenced the genomic region that encodes EDN1 in 942 Japanese hypertensive patients. We identified a novel missense mutation, G36R, in one hypertensive patient, but no mutations were observed in EDN1. A gene polymorphism in *EDN1*, Lys198Asn, has been reported to be associated with hypertension in obese subjects. Taken together, these findings reveal that the EDN-ECE pathway is an important system involved in essential hypertension in Japanese. (*Hypertens Res* 2007; 30: 513–520)

Key Words: endothelin, endothelin-converting enzyme, gene variants, hypertension, general population

From the ¹⁾Research Institute, Divisions of ³⁾Hypertension and Nephrology and ⁴⁾Preventive Cardiology, National Cardiovascular Center, Suita, Japan; and ²⁾Department of Information, Environmental and Food Sciences, Faculty of Education, Art and Sciences, Yamagata University, Yamagata, Japan.

This study was supported by the Program for Promotion of Fundamental Studies in Health Science of the Pharmaceuticals and Medical Devices Agency (PMDA), the Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation (NIBIO) of Japan and a Grant-in-Aid from the Ministry of Health, Labor, and Welfare of Japan and a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.

Address for Reprints: Kei Kamide, M.D., Ph.D., Division of Hypertension and Nephrology, National Cardiovascular Center, 5–7–1 Fujishirodai, Suita 565–8565, Japan. E-mail: kamide@hsp.ncvc.go.jp

Received December 28, 2005; Accepted in revised form January 25, 2007.

Introduction

The endothelin (EDN) system is comprised of 4 active EDNs, with EDN1 being the predominant isoform in the cardiovascular system (1). Because of the potent vasoconstricting and mitogenic effects of EDN1 and its involvement in various cardiovascular diseases, biosynthesis of EDN1 has received considerable attention. EDN1 is synthesized from a 212-amino acid precursor protein, preproEDN1, through multiple proteolytic steps. In the first step, preproEDN1 is cleaved by a signal peptidase, resulting in the formation of proEDN1, which is then cleaved by a furin-like enzyme to yield the 38-amino acid protein known as big-EDN1 (amino acids 53–92) or other intermediates. Big-EDN1 is subsequently cleaved by a unique type II metalloprotease, EDN-converting enzyme-1 (ECE1), to yield EDN1 (amino acids 53–73) (2).

The EDN system is a promising target for the genetic analysis for hypertension. The missense mutation Lys198Asn has been identified in preproEDN1, and several reports have described that this polymorphism showed a positive association with blood pressure elevation in overweight people (3–5), although no significant difference in the EDN1 levels between the Asn-type and Lys-type transfectant was observed in an expression analysis (6). As for *ECE1*, an association between the –338C>A polymorphism in *ECE1* and blood pressure levels in women but not in men has recently been reported (7). This C>A polymorphism is associated with increased promoter activity, as demonstrated in a promoter assay analysis (8).

Complex traits such as hypertension, diabetes mellitus, and hyperlipidemia are suggested to be caused by common sequence variants that may have a small to moderate phenotypic effect (9–11). On the other hand, accumulating data has shown that most Mendelian disorders are caused by a set of different mutations that often reside in coding regions. These rare variants tend to have strong phenotypic effects. Several recent studies have shown that rare genetic variations in *ABCA1*, *APOA1*, and *LCAT* collectively contribute to the variation in plasma levels of high-density lipoprotein (HDL) cholesterol in the general population (12, 13). We hypothesized that rare genetic variations in hypertension candidate genes could collectively contribute to hypertension. To investigate this hypothesis, we have been identifying such mutations in Japanese hypertensive subjects; to date, we have identified missense mutations in the β - or γ -subunit of the amiloride-sensitive epithelial sodium channel encoded by *SCNN1B* and *SCNN1G* (14), a causative gene for pseudohypaldosteronism type II encoded by serine-threonine kinase *WNK4* (15), the regulator of G-protein signaling 2 (*RGS2*) (16), and the mineralocorticoid receptor encoded by *NR3C2* (17). As the next hypertension candidate gene, we have begun to sequence the *EDN1* gene and to search for missense mutations (18).

In present study, we genotyped the genetic polymorphisms

of one of the EDN-converting enzymes, the *ECE1* gene, in a general Japanese population to examine whether the *ECE1* gene is a susceptibility gene for hypertension. Secondly, to evaluate the EDN system in essential hypertension in Japanese, we re-sequenced the EDN1 polypeptide in the *EDN1* gene in Japanese hypertensive patients to identify missense mutations that may deleteriously affect EDN1 function.

Methods

General Population

The selection criteria and design of the Suita study have been described previously (19, 20). Only those who gave written informed consent for genetic analyses were included in this study. The study protocol was approved by the Ethical Review Committee of the National Cardiovascular Center. In this study, the genotypes of 1,873 samples were determined. The characteristics of the 1,873 participants (863 men and 1,010 women) are shown in Table 1. Routine blood examinations that included total serum cholesterol, HDL cholesterol, triglyceride, and glucose levels were performed. A physician or nurse interviewed each patient regarding smoking and alcohol drinking habits and personal history of cardiovascular disease, including angina pectoris, myocardial infarction, and/or stroke. Blood pressure was measured after at least 10 min of rest in a sitting position. Systolic and diastolic blood pressures (SBP and DBP) were the means of two measurements by well-trained doctors (recorded >3 min apart). Hypertension was defined as SBP of ≥ 140 mmHg, DBP of ≥ 90 mmHg, or the current use of antihypertensive medication (20). Diabetes mellitus was defined as fasting plasma glucose ≥ 7.0 mmol/L (126 mg/dL), non-fasting plasma glucose ≥ 11.1 mmol/L (200 mg/dL), current use of antidiabetic medication, or HbA1c $\geq 6.5\%$. Hyperlipidemia was defined as total cholesterol ≥ 5.68 mmol/L (220 mg/dL) or antihyperlipidemia medication. Body mass index (BMI) was calculated as weight (in kg) divided by height (in m) squared.

Hypertensive Subjects

A total of 942 hypertensive subjects (518 men and 424 women; average age: 65.1 ± 10.5 years) were recruited from the Division of Hypertension and Nephrology at the National Cardiovascular Center. Ninety-two percent of study subjects (870 subjects) were diagnosed with essential hypertension, and the rest had secondary hypertension, including renal hypertension (36 subjects), renovascular hypertension (23 subjects), primary aldosteronism (11 subjects) and hypothyroid-induced hypertension (2 subjects) (14–17). The hypertension criteria were blood pressure above 140 and/or 90 mmHg or the use of antihypertensive agents. Blood pressure was the average of three measurements taken in a sitting position after at least 5 min of rest on each occasion. About one-third of the hypertensive subjects had hypertensive cardiovas-

Table 1. Basic Characteristics of Subjects in Japanese General Population (Suita Study)

	Women (n=1,010)	Men (n=863)
Age (years old)	63.3±11.0	66.3±11.1*
Systolic blood pressure (mmHg)	128.0±19.6	131.9±19.5*
Diastolic blood pressure (mmHg)	76.6±9.8	79.7±10.7*
Body mass index (kg/m ²)	22.3±3.2	23.3±3.0*
Total cholesterol (mmol/L)	5.57±0.79*	5.10±0.78
HDL-cholesterol (mmol/L)	1.67±0.40*	1.42±0.36
Current smokers (%)	6.3	30.1 [†]
Current drinkers (%)	29.3	67.0 [†]
Present illness (%)		
Hypertension	38.2	47.4 [†]
Hyperlipidemia	55.2 [†]	27.4
Diabetes mellitus	5.2	12.6 [†]

Values are mean±SD or percentage. Hypertension: systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg or antihypertensive medication; hyperlipidemia: total cholesterol ≥220 mg/dL or antihyperlipidemia medication; diabetes: fasting plasma glucose ≥126 mg/dL or non-fasting plasma glucose ≥200 mg/dL or HbA1c ≥6.5% or antidiabetic medication. **p*<0.05 between women and men by Student's *t*-test. [†]*p*<0.05 between women and men by χ^2 test. HDL, high-density lipoprotein.

cular complications. The clinical features of the patients in this study are summarized in Table 2.

All of the participants for the genetic analysis in the present study gave their written informed consent. The study protocol was approved by the Ethical Review Committee of the National Cardiovascular Center.

Genotyping of Mutations of Single Nucleotide Polymorphisms of the *ECE1* Gene in the General Population

We obtained genetic polymorphisms in the *ECE1* gene using the database of Japanese Single Nucleotide Polymorphisms (JSNP) (<http://snp.ims.u-tokyo.ac.jp/>) (21, 22) and genotyped the following 5 single nucleotide polymorphisms (SNPs) by the TaqMan-PCR system: rs212548-TC (IMS-JST017298 in intron 4), rs212528-TC (IMS-JST004319 in intron 5), rs212526-CT (IMS-JST009090 in intron 6), rs2038090-AC (IMS-JST004325 in intron 17), and rs2038089-AG (IMS-JST004324 in intron 17). The primers and probes of the TaqMan-PCR system are available on request. Hereafter, SNPs are described according to the RS nomenclature system.

Screening of Mutations in Exon 2 of the *EDN1* Gene

Blood samples were obtained from each subject and genomic

Table 2. General Characteristics of Patients with Hypertension and/or Renal Failure

	Number	942
Age (years)		65.1±10.5
Gender (M/F)		518/424
Body mass index (kg/m ²)		24.2±3.3
Systolic blood pressure (mmHg)		145.5±19.2
Diastolic blood pressure (mmHg)		84.8±13.4
Essential hypertension		870
Secondary hypertension		72
Renal hypertension		36
Renovascular hypertension		23
Primary aldosteronism		11
Hypothyroid-induced hypertension		2
Renal impairment*		110
Ischemic heart disease		102
Stroke**		145

Values are expressed as mean±SD. *Patients who had serum creatinine ≥1.4 mg/dL. **Silent cerebral infarction was included. M, male; F, female.

DNA was isolated from peripheral blood leukocytes using an NA-3000 nucleic acid isolation system (KURABO, Osaka, Japan). The region of exon 2 was amplified by polymerase chain reaction (PCR) using a pair of specific primers, 5'-CTGATGGCAGGCTGTGTGCTT-3' and 5'-CCCCATCAG ATGCCACTGTGA-3', which flank the 612-bp region containing exon 2. The PCR products were directly sequenced on an ABI PRISM 3700 DNA analyzer (Applied Biosystems, Foster City, USA) as described previously (23, 24). The obtained sequences were examined for the presence of mutations using Sequencher software (Gene Codes Corporation, Ann Arbor, USA), followed by visual inspection (25).

Statistical Analysis

Analysis of variance was used to compare mean values between groups, and if overall significance was demonstrated, the intergroup difference was assessed by means of a general linear model. Frequencies were compared by χ^2 analysis. Association analyses between genotypes and blood pressure in each sex were performed through logistic regression analysis with consideration for potential confounding risk variables, including age, BMI, present illness (hyperlipidemia and diabetes mellitus), lifestyle (smoking and drinking), and antihypertensive medication. For multivariate risk predictors, the adjusted odds ratios were given with the 95% confidence intervals. The relationship between genotypes and risk of hypertension was expressed in terms of the odds ratios adjusted for possible confounding effects, including age, BMI, present illness (hyperlipidemia and diabetes mellitus), and lifestyle (smoking and drinking). Odds ratios were calculated as a measure of the association between each genotype

Table 3. Odds Ratio of Polymorphisms in *ECE1*

SNP	Sex	Genotype	n	Odds ratio	(95% CI)	p	Genotype	n	Odds ratio	(95% CI)	p
rs212548	Women	TT	328	1	(reference)		TT+TC	821	1	(reference)	
		TC+CC	686	1.28	(0.94–1.74)	0.116	CC	193	1.21	(0.85–1.72)	0.293
	Men	TT	275	1	(reference)		TT+TC	692	1	(reference)	
		TC+CC	590	1.10	(0.82–1.50)	0.520	CC	173	0.98	(0.69–1.40)	0.924
rs212528	Women	TT	663	1	(reference)		TT+TC	980	1	(reference)	
		TC+CC	347	1.40	(1.04–1.89)	0.026	CC	30	1.63	(0.74–3.58)	0.227
	Men	TT	528	1	(reference)		TT+TC	827	1	(reference)	
		TC+CC	335	0.83	(0.62–1.11)	0.198	CC	36	0.75	(0.37–1.53)	0.428
rs212526	Women	CC	734	1	(reference)		CC+CT	996	1	(reference)	
		CT+TT	280	0.76	(0.55–1.05)	0.099	TT	18	0.77	(0.25–2.35)	0.650
	Men	CC	615	1	(reference)		CC+CT	842	1	(reference)	
		CT+TT	251	0.95	(0.70–1.30)	0.751	TT	24	1.40	(0.58–3.38)	0.455
rs2038090	Women	AA	774	1	(reference)		AA+AC	999	1	(reference)	
		AC+CC	239	1.17	(0.84–1.64)	0.348	CC	14	1.05	(0.30–3.61)	0.939
	Men	AA	676	1	(reference)		AA+AC	856	1	(reference)	
		AC+CC	189	1.00	(0.71–1.40)	0.989	CC	9	3.32	(0.67–16.45)	0.142
rs2038089	Women	AA	414	1	(reference)		AA+AG	880	1	(reference)	
		AG+GG	598	1.19	(0.89–1.59)	0.240	GG	132	1.21	(0.80–1.84)	0.358
	Men	AA	380	1	(reference)		AA+AG	788	1	(reference)	
		AG+GG	486	1.12	(0.84–1.49)	0.450	GG	78	1.33	(0.81–2.18)	0.264

*Conditional logistic analysis, adjusted for age, body mass index, present illness (hyperlipidemia and diabetes mellitus), and lifestyle (smoking and drinking). SNP, single nucleotide polymorphism; CI, confidence interval.

Table 4. Association of Genotypes with Blood Pressure Variation

SNP	Genotype	Women				Men					
		n	DBP (mmHg)	p*	SBP (mmHg)	p*	n	DBP (mmHg)	p*	SBP (mmHg)	p*
rs212528	TT	663	76.49±0.37		126.89±0.64		528	79.98±0.43		131.94±0.75	
	TC	317	76.55±0.53		129.21±0.93		299	79.48±0.57		131.18±1.00	
	CC	30	77.57±1.72	0.698	133.33±3.02	0.007	36	80.93±1.66	0.931	133.83±2.89	0.941
	TT	663	76.49±0.37		126.89±0.64		528	79.98±0.43		131.94±0.75	
	TC+CC	347	76.63±0.51	0.823	129.56±0.89	0.016	335	79.64±0.54	0.840	131.47±0.94	0.698
	TT+TC	980	76.51±0.30		127.64±0.53		827	79.67±0.34		131.66±0.60	
rs212526	CC	734	76.56±0.35		128.07±0.61		615	79.41±0.40		131.67±0.69	
	CT	262	76.90±0.58		127.51±1.03		227	80.15±0.66		131.39±1.15	
	TT	18	70.08±2.19	0.344	120.04±3.87	0.175	24	84.13±2.06	0.048	138.16±3.59	0.422
	CC	734	76.56±0.35		128.07±0.61		615	79.41±0.40		131.67±0.69	
	CT+TT	280	76.45±0.56	0.874	127.02±0.99	0.371	251	80.52±0.63	0.135	132.03±1.09	0.780
	CC+CT	996	76.65±0.30		127.92±0.52		842	79.61±0.34		131.59±0.59	
TT	18	70.08±2.19	0.003	120.04±3.87	0.044	24	84.13±2.06	0.030	138.16±3.59	0.071	

Values are mean±SEM. *Conditional logistic analysis, adjusted for age, body mass index (BMI), present illness (hyperlipidemia and diabetes mellitus), and lifestyle (smoking and drinking). SNP, single nucleotide polymorphism; DBP, diastolic blood pressure; SBP, systolic blood pressure.

and hypertension under the assumption of a dominant (with scores of 0 for patients homozygous for the major allele and 1

for carriers of the minor allele) or recessive (with scores of 0 for carriers of the major allele and 1 for patients homozygous

Table 5. Haplotype Frequency (Freq) of *ECE1* Gene in Hypertensives (HT) and Normotensives (NT)

Haplotype	All				Men				Women			
	Freq (%)	χ^2	<i>P</i>		Freq (%)	χ^2	<i>P</i>		Freq (%)	χ^2	<i>P</i>	
			Asymptotic	Permutation			Asymptotic	Permutation			Asymptotic	Permutation
H1 T/T/C/A/A Overall	19.2	1.278	0.258	0.327	19.0	0.040	0.841	0.893	19.3	2.954	0.086	0.127
NT	19.8				18.8				20.4			
HT	18.4				19.2				17.3			
H2 C/C/C/A/A Overall	16.2	1.305	0.253	0.284	17.5	0.193	0.661	0.669	15.1	2.991	0.084	0.091
NT	15.5				17.9				14.0			
HT	16.9				17.1				16.9			
H3 T/T/C/A/G Overall	14.3	0.122	0.727	0.769	14.7	0.231	0.631	0.695	14.2	0.060	0.807	0.825
NT	14.1				14.4				14.0			
HT	14.5				15.2				14.4			
H4 C/T/C/A/A Overall	11.8	0.181	0.670	0.716	11.9	0.033	0.857	0.867	11.8	0.250	0.617	0.699
NT	12.0				12.1				12.1			
HT	11.5				11.8				11.4			
H5 T/T/T/A/A Overall	10.7	8.254	0.004	0.015	10.9	0.421	0.516	0.575	10.6	11.865	0.001	0.003
NT	12.0				11.4				12.4			
HT	9.0				10.4				7.5			
H6 T/T/C/C/G Overall	8.3	0.317	0.574	0.618	7.8	0.327	0.568	0.624	9.0	0.001	0.974	0.978
NT	8.1				8.1				9.0			
HT	8.7				7.3				9.0			
H7 C/T/C/A/G Overall	7.8	0.133	0.715	0.775	6.2	1.115	0.291	0.402	8.8	2.071	0.150	0.192
NT	7.6				5.5				8.2			
HT	7.9				6.7				10.0			

Haplotypes (rs212548/rs212528/rs212526/rs2038090/rs2038089) with frequencies of more than 5% are shown. One hundred thousand replicates were used for permutation test for all, men and women. Numbers of haplotypes in Overall, NT, and HT are 3,736, 2,150, 1,586 for All; 1,730, 914, 816 for men; and 2,030, 1,254, 776 for women, respectively.

for the minor allele) mode of inheritance. The *p* values were adjusted by Bonferroni correction. SAS statistical software (release 6.12; SAS Institute Inc., Cary, USA) was used for the statistical analyses. The data of linkage disequilibrium, haplotype blocks and coverage of HapMap SNPs were downloaded from the HapMap Consortium (<http://www.hapmap.org>). Haplotypes and permutation analyses were calculated using SNPalyze version 4.0 software (DYNACOM Co., Mobar, Japan).

Results

Association between SNPs in the *ECE1* Gene and Hypertension

Five genetic polymorphisms in the *ECE1* gene were genotyped in 1,873 individuals. The genotype frequencies for each polymorphism were as follows: rs212548-T>C, 0.563/0.437; rs212528-T>C, 0.800/0.200; rs212526-C>T, 0.848/0.152; rs2038090-A>C, 0.880/0.120; rs2038089-A>G, 0.655/0.345. None of the genotype frequencies were significantly different from those expected from the Hardy-Weinberg equilibrium ($p > 0.05$). Multiple logistic regression analysis after

adjusting for confounding factors of age, BMI, hyperlipidemia, diabetes mellitus, smoking, and drinking revealed that one polymorphism, rs212528, in intron 5 was significantly associated with hypertension in women (rs212528-T>C: TT vs. TC+CC; odds ratio=1.40; 95% confidence interval: 1.04–1.89; $p=0.026$) (Table 3). The SBPs in women with the TT, TC, and CC genotypes were 126.89 ± 0.64 mmHg ($n=663$), 129.21 ± 0.93 mmHg ($n=317$), and 133.33 ± 3.02 mmHg ($n=30$) ($p=0.007$), after adjusting for the same confounding factors (Table 4). Thus, the difference in SBP was 6.44 mmHg between women with the CC genotype and those with the TT genotype. This association was still significant even after the Bonferroni correction.

Another polymorphism, rs212526, was associated with a significant difference in DBP: women having the CC+CT genotype had a DBP of 76.65 ± 0.30 mmHg ($n=996$) and those with the TT genotype had a DBP of 70.08 ± 2.19 mmHg ($n=18$) ($p=0.003$) after adjusting for the same confounding factors (Table 4). This polymorphism was also significantly associated with the SBP in women (CC+CT: 127.92 ± 0.52 mmHg, $n=996$; TT: 120.04 ± 3.87 mmHg, $n=18$; $p=0.044$). However, this polymorphism did not show a significant association with hypertension. In men, this polymorphism was

Table 6. List of 5 Polymorphisms and Their Allele Frequency in Exon 2 of *EDN1* Identified by Direct Sequencing of 942 Hypertensive Japanese

Allele 1 > allele 2	Amino acid change	region	Allele frequency		Flanking sequence	rs ID
			Allele 1	Allele 2		
1753G>A	G36R	exon 2	1.000	0.000	TGAGAACGGC[G/A]GGGAGAAACC	rs2070699
1910G>T		intron 2	0.473	0.527	TGTAACCCTA[G/T]TCATTCATTA	
1918T>A		intron 2	0.999	0.001	TAGTCATTCA[T/A]TAGCGCTGGC	
2008G>A		intron 2	0.999	0.001	GTGCCTCAGT[G/A]GGGACAGTTT	
2107G>A		intron 2	0.999	0.001	TACTCATGAT[G/A]GGACAAGCAG	

The A of the ATG of the initiator Met codon is denoted nucleotide +1, as recommended by the Nomenclature Working Group (28). The nucleotide number was according to the reference sequences GenBank Accession ID: NT_007592.




Fig. 1. Genome and domain structure of human endothelin 1. Two missense mutations in endothelin-1, Gly36Arg (G36R) and Lys198Asn (K198N), are shown. The G36R mutation in preproendothelin-1 was identified in this study.

significantly associated with DBP (CC+CT: 79.61±0.34 mmHg, n=842; TT: 84.13±2.06 mmHg, n=24; p=0.030).

The haplotypes composed of the 5 SNPs genotyped in this study are shown in Table 5. Seven inferred haplotypes with frequencies of more than 5% were examined to determine their association with hypertension in all patients and in two sub-populations (men and women). In women, the frequency of haplotype H5 in the hypertensive group was significantly lower than that in the normotensive group.

A Novel Missense Mutation in the preproEDN1 Polypeptide in Japanese Hypertensives

We sequenced the region of exon 2 of *EDN1* in 942 hypertensive patients with strong genetic background and secondary hypertension. The results are shown in Table 6. In this study, we were not able to detect any missense mutations within the mature EDN1 region. However, we identified one novel missense mutation, G36R, in *EDN1* in a heterozygous form in a male patient. The prevalence of this mutation was 0.05% in our Japanese hypertensive population. We tried to screen this missense mutation, G36R in *EDN1*, in our general population by the TaqMan-PCR method, but this genotyping failed due

to technical problems.

Discussion

In this study, we used two different approaches to reveal the contribution of the EDN system to hypertension in two different populations, a general population and a hypertensive population, both from the Osaka region in Japan.

We genotyped 5 SNPs in *ECE1* and identified rs212528 as the hypertension/blood pressure susceptibility genetic variant. We used the currently available HapMap data from CHB-JPN to assess the coverage of haplotype blocks across the *ECE1* gene by 5 SNPs. The *ECE1* gene consisted of 6 haplotype blocks, in which rs212548 was present in block 2, two SNPs, rs212528 and rs212526, were present in block 3, and two SNPs, rs2038090 and rs2038089, were present in block 6, and the genotyped SNPs were estimated to cover approximately 90% of the haplotypes in block 2, 30% of those in block 3, and 90% of those in block 6, respectively. Two SNPs, rs212528 and rs212526, in block 3 had an *r*² of 0.031 and LOD score of 0.43, and rs2038090 and rs2038089 in block 6 had an *r*² of 0.163 and LOD score of 2.33.

In this study, the rs212528-T>C polymorphism in *ECE1* in

women was identified as the SNP conferring susceptibility for hypertension and blood pressure change. It is well known that the incidence of coronary artery disease shows a gender difference that may in part be related to the female sex hormones estrogen and progesterone. The literature provides evidence that estrogen inhibits EDN1 production (26). Furthermore, estrogen inhibits ECE-1 mRNA expression (27). These findings may explain the gender difference of *ECE1* polymorphisms for hypertension. The mean age of women in our population was 63.3 years. Despite the relatively advanced age of this population, we identified a contribution of the rs212528 polymorphism to hypertension and blood pressure change, while haplotypes containing the rs212528-C allele were not clearly associated with normotension or hypertension. The association might have been stronger if we had used a younger female population.

Another polymorphism, rs212526-C>T in intron 6, was associated with a blood pressure change in women and men. The mean DBP of the 996 women with the CC+CT genotype was 6.57 mmHg higher than that of the 18 women with the TT genotype ($p=0.003$), and the SBP change also showed the same trend—that is, women with the CC+CT genotype had higher blood pressure than women with the TT genotype ($p=0.044$) (Table 4). However, in men, the opposite trend was seen. The mean DBP of the 842 men with the CC+CT genotype was 4.52 mmHg lower than that of the 24 men with the TT genotype ($p=0.030$). Haplotype H5 containing the rs212528-T allele was significantly more prevalent in the normotensive group. This association also suggested that the T-allele of rs212528 was involved in blood pressure in women (Tables 3–5). Thus, the significance of rs212526 on blood pressure change should be evaluated using other population.

The association of SNP with hypertension and blood pressure change is at best marginally significant given the number of tests performed. All the p -values were more than 0.007. However, rs212528 is present in the *ECE1* gene, which encodes the endothelin-converting enzyme. In addition, this SNP showed a positive association with both hypertension and blood pressure change. Thus, we regarded this SNP as a hypertension candidate. SNP and blood pressure/hypertension described in the present study needs to be confirmed by another set of studies.

In the hypertensive population, we sequenced the coding region of the EDN1 polypeptide and its flanking region in 942 Japanese hypertensives and identified one novel missense mutation, G36R, that was not present in the EDN1 polypeptide but was present in the preproEDN-1 region (Fig. 1). At present, the effect of G36R mutation on the EDN1 function is not clear, because it was located far from the scissile site, the R52–C53 bond, by the furin-like enzyme. From the evolutionary point of view, G36 was conserved in humans, chimpanzees, cows, and dogs, but mice and rats have Val and chickens have Ala. The arginine residue at position 36 was not found in preproEDN1 in any species. To reveal the functional effect of this missense mutation on the processing of

preproEDN1, an expression study of the mutant preproEDN1 is needed.

We have hypothesized that rare nonsynonymous mutations in candidate genes could collectively contribute to complex traits. In this model, the extensive sequence-based approaches focusing on identification of these mutations is necessary. So far, we have sequenced several hypertension candidate genes to evaluate whether rare variants could contribute to the etiology of hypertension. At present, however, whether rare variants contribute to hypertension is not clear due to the lack of *in vitro* or *in vivo* expression studies of the mutant protein (14, 15, 17). The exception was the nonsense mutation identified in the *RGS2* gene, which has been clearly shown to produce the defective protein (16). In this study, we identified one missense mutation, G36R, in preproEDN1. The further collection of such missense mutations in hypertension candidate genes could lead to an enhanced understanding of the etiology of essential hypertension.

In summary, we revealed that the rs212528 polymorphism in *ECE1* was associated with hypertension and blood pressure change. In earlier reports, the Lys198Asn polymorphism in *EDN1* showed a positive association with blood pressure elevation in overweight people (3–5). Thus, endothelin family gene polymorphisms might play an important role in the etiology of essential hypertension.

Acknowledgements

We would like to express our gratitude to Dr. Otsaburo Hishikawa, Dr. Katsuyuki Kawasaki, Mr. Tadashi Fujikawa, and the members of the Satsuki-Junyukai for their continuous support of our population survey in Suita City. We also thank all the staff in the Division of Preventive Cardiology for their help with the medical examination.

References

1. Yanagisawa M, Kurihara H, Kimura S, et al: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. *Nature* 1988; 332: 411–415.
2. Miyauchi T, Masaki T: Pathophysiology of endothelin in the cardiovascular system. *Annu Rev Physiol* 1999; 61: 391–415.
3. Tiret L, Poirier O, Hallet V, et al: The Lys198Asn polymorphism in the endothelin-1 gene is associated with blood pressure in overweight people. *Hypertension* 1999; 33: 1169–1174.
4. Asai T, Ohkubo T, Katsuya T, et al: Endothelin-1 gene variant associates with blood pressure in obese Japanese subjects: the Ohasama Study. *Hypertension* 2001; 38: 1321–1324.
5. Jin JJ, Nakura J, Wu Z, et al: Association of endothelin-1 gene variant with hypertension. *Hypertension* 2003; 41: 163–167.
6. Tanaka C, Kamide K, Takiuchi S, et al: Evaluation of the Lys198Asn and –134delA genetic polymorphisms of the endothelin-1 gene. *Hypertens Res* 2004; 27: 367–371.

7. Funalot B, Courbon D, Brousseau T, *et al*: Genes encoding endothelin-converting enzyme-1 and endothelin-1 interact to influence blood pressure in women: the EVA study. *J Hypertens* 2004; 22: 739–743.
8. Funke-Kaiser H, Reichenberger F, Kopke K, *et al*: Differential binding of transcription factor E2F-2 to the endothelin-converting enzyme-1b promoter affects blood pressure regulation. *Hum Mol Genet* 2003; 12: 423–433.
9. Risch N, Merikangas K: The future of genetic studies of complex human diseases. *Science* 1996; 273: 1516–1517.
10. Collins FS, Guyer MS, Chakravarti A: Variations on a theme: cataloging human DNA sequence variation. *Science* 1997; 278: 1580–1581.
11. Lander ES: The new genomics: global views of biology. *Science* 1996; 274: 536–539.
12. Cohen JC, Kiss RS, Pertsemlidis A, *et al*: Multiple rare alleles contribute to low plasma levels of HDL cholesterol. *Science* 2004; 305: 869–872.
13. Frikke-Schmidt R, Nordestgaard BG, Jensen GB, *et al*: Genetic variation in ABC transporter A1 contributes to HDL cholesterol in the general population. *J Clin Invest* 2004; 114: 1343–1353.
14. Kamide K, Tanaka C, Takiuchi S, *et al*: Six missense mutations of the epithelial sodium channel β and γ subunits in Japanese hypertensives. *Hypertens Res* 2004; 27: 333–338.
15. Kamide K, Takiuchi S, Tanaka C, *et al*: Three novel missense mutations of *WNK4*, a kinase mutated in inherited hypertension, in Japanese hypertensives: implication of clinical phenotypes. *Am J Hypertens* 2004; 17: 446–449.
16. Yang J, Kamide K, Kokubo Y, *et al*: Genetic variations of regulator of G-protein signaling 2 in hypertensive patients and in the general population. *J Hypertens* 2005; 23: 1497–1505.
17. Kamide K, Yang J, Kokubo Y, *et al*: A novel missense mutation, F826Y, in the mineralocorticoid receptor gene in Japanese hypertensives: implication of clinical phenotypes. *Hypertens Res* 2005; 28: 703–709.
18. Vanhoutte PM, Feletou M, Taddei S: Endothelium-dependent contractions in hypertension. *Br J Pharmacol* 2005; 144: 449–458.
19. Mannami T, Baba S, Ogata J: Strong and significant relationships between aggregation of major coronary risk factors and the acceleration of carotid atherosclerosis in the general population of a Japanese city: the Suita Study. *Arch Intern Med* 2000; 160: 2297–2303.
20. Kokubo Y, Inamoto N, Tomoike H, *et al*: Association of genetic polymorphisms of sodium-calcium exchanger 1 gene, *NCX1*, with hypertension in a Japanese general population. *Hypertens Res* 2004; 27: 697–702.
21. Haga H, Yamada R, Ohnishi Y, *et al*: Gene-based SNP discovery as part of the Japanese Millennium Genome Project: identification of 190,562 genetic variations in the human genome. Single-nucleotide polymorphism. *J Hum Genet* 2002; 47: 605–610.
22. Hirakawa M, Tanaka T, Hashimoto Y, *et al*: JSNP: a database of common gene variations in the Japanese population. *Nucleic Acids Res* 2002; 30: 158–162.
23. Okuda T, Fujioka Y, Kamide K, *et al*: Verification of 525 coding SNPs in 179 hypertension candidate genes in the Japanese population: identification of 159 SNPs in 93 genes. *J Hum Genet* 2002; 47: 387–394.
24. Matayoshi T, Kamide K, Takiuchi S, *et al*: The thiazide-sensitive $\text{Na}^+\text{-Cl}^-$ cotransporter gene, *C1784T*, and adrenergic receptor- $\beta 3$ gene, *T727C*, may be gene polymorphisms susceptible to the antihypertensive effect of thiazide diuretics. *Hypertens Res* 2004; 27: 821–833.
25. Kokubo Y, Kamide K, Inamoto N, *et al*: Identification of 108 SNPs in *TSC*, *WNK1*, and *WNK4* and their association with hypertension in a Japanese general population. *J Hum Genet* 2004; 49: 507–515.
26. Webb CM, Ghatei MA, McNeill JG, *et al*: 17β -Estradiol decreases endothelin-1 levels in the coronary circulation of postmenopausal women with coronary artery disease. *Circulation* 2000; 102: 1617–1622.
27. Rodrigo MC, Martin DS and Eyster KM: Vascular ECE-1 mRNA expression decreases in response to estrogens. *Life Sci* 2003; 73: 2973–2983.
28. Antonarakis SE, Nomenclature Working Group: Recommendations for a nomenclature system for human gene mutations. *Hum Mut* 1998; 11: 1–3.

Sex Hormone and Gender Difference—Role of Testosterone on Male Predominance in Brugada Syndrome

WATARU SHIMIZU, M.D., PH.D.,* KIYOTAKA MATSUO, M.D., PH.D.,†
 YOSHIHIRO KOKUBO, M.D., PH.D.,‡ KAZUHIRO SATOMI, M.D., PH.D.,*
 TAKASHI KURITA, M.D., PH.D.,* TAKASHI NODA, M.D., PH.D.,*
 NORITOSHI NAGAYA, M.D., PH.D.,* KAZUHIRO SUYAMA, M.D., PH.D.,*
 NAOHIKO AIHARA, M.D.,* SHIRO KAMAKURA, M.D., PH.D.,*
 NOZOMU INAMOTO, M.D., PH.D.,‡ MASAZUMI AKAHOSHI, M.D., PH.D.,¶
 and HITONOBU TOMOIKE, M.D., PH.D.*

From the *Division of Cardiology, Department of Internal Medicine; †Department of Preventive Cardiology, National Cardiovascular Center, Suita, Japan; ‡Department of Cardiovascular Medicine, Nagasaki University Graduate School of Medicine; and ¶Department of Clinical Studies, Radiation Effects Research Foundation, Nagasaki, Japan

Testosterone in Brugada Syndrome. *Introduction:* The clinical phenotype is 8 to 10 times more prevalent in males than in females in patients with Brugada syndrome. Brugada syndrome has been reported to be thinner than asymptomatic normal controls. We tested the hypothesis that higher testosterone level associated with lower visceral fat may relate to Brugada phenotype and male predominance.

Methods and Results: We measured body-mass index (BMI), body fat percentage (BF%), and several hormonal levels, including testosterone, in 48 Brugada males and compared with those in 96 age-matched control males. Brugada males had significantly higher testosterone (631 ± 176 vs 537 ± 158 ng/dL; $P = 0.002$), serum sodium, potassium, and chloride levels than those in control males by univariate analysis, and even after adjusting for age, exercise, stress, smoking, and medication of hypertension, diabetes, and hyperlipidemia, whereas there were no significant differences in other sex and thyroid hormonal levels. Brugada males had significantly lower BMI (22.1 ± 2.9 vs 24.6 ± 2.6 kg/m²; $P < 0.001$) and BF% (19.6 ± 4.9 vs $23.1 \pm 4.7\%$; $P < 0.001$) than control males. Testosterone level was inversely correlated with BMI and BF% in both groups, even after adjusting for the confounding variables. Conditional logistic regression models showed significant positive and inverse association between Brugada syndrome and hypertestosteronemia (OR:3.11, 95% CI:1.22–7.93, $P = 0.017$) and BMI (OR:0.72, 95% CI:0.61–0.85, $P < 0.001$), respectively.

Conclusions: Higher testosterone level associated with lower visceral fat may have a significant role in the Brugada phenotype and male predominance in Brugada syndrome. (*J Cardiovasc Electrophysiol*, Vol. 18, pp. 415-421, April 2007)

Brugada syndrome, gender, sex hormones, testosterone, body mass index

Introduction

Brugada syndrome is characterized by coved-type ST-segment elevation in the right precordial electrocardiographic (ECG) leads (V1–V3) and an episode of ventricular fibrillation (VF) in the absence of structural heart disease.^{1–5} The

prevalence of the disease is estimated to be up to 5 per 10,000 inhabitants and is one of the important causes of sudden cardiac death of middle-aged males, particularly in Asian countries including Japan.⁴

More than eight dozen distinct mutations in *SCN5A*, the gene encoding the α subunit of the sodium channel, have been so far identified in patients with Brugada syndrome and all mutations display an autosomal-dominant mode of transmission.^{6,7} Therefore, males and females are expected to inherit the defective gene equally. However, more than 80% of patients in Western countries and more than 90% of patients in Asian countries affected with Brugada syndrome are males.⁸ Recent experimental studies have unveiled the cellular mechanism of Brugada phenotype. The male predominance in the Brugada syndrome is suggested to be due, at least in part, to intrinsic differences in ventricular action potential (AP) between males and females.⁹

A male hormone, testosterone is reported to increase net outward currents^{10–12} and is expected to accentuate Brugada phenotype, such as ST-segment elevation and subsequent episodes of VF in patients with Brugada syndrome. Testosterone is also known to decrease visceral fat.^{13–15} Since patients with Brugada syndrome have been reported to be

Dr. W. Shimizu was supported by the Hoansha Research Foundation, Japan Research Foundation for Clinical Pharmacology, Ministry of Education, Culture, Sports, Science, and Technology Leading Project for Biosimulation, and health sciences research grants (H18—Research on Human Genome—002) from the Ministry of Health, Labor, and Welfare, Japan. Drs. Y. Kokubo, N. Inamoto, and H. Tomoike were supported by the Program for the Promotion of Fundamental Studies in Health Science of the Organization for Pharmaceutical Safety and Research of Japan (MPJ-3).

Address for correspondence: Wataru Shimizu, M.D., Ph.D., Division of Cardiology, Department of Internal Medicine, National Cardiovascular Center, 5-7-1 Fujishiro-dai, Suita, Osaka, 565-8565 Japan. Fax: 81-6-6872-7486; E-mail: wshimizu@hsp.nccvc.go.jp

Manuscript received 11 September 2006; Revised manuscript received 2 November 2006; Accepted for publication 15 November 2006.

doi: 10.1111/j.1540-8167.2006.00743.x

thinner than asymptomatic normal controls by Matsuo et al.,¹⁶ we speculated that higher testosterone level associated with lower visceral fat may modulate Brugada phenotype and may relate to male predominance in patients with Brugada syndrome.

Methods

Patient Population and Data Collection

The study population consisted of 48 males with Brugada syndrome who agreed to participate in this study and showed Type 1 "coved" ST-segment elevation in V1–V3 leads¹⁷ ranging in age from 30 to 69 years with a mean age of 50 ± 11 years (mean \pm SD). Brugada males who were less than 30 years old and more than 70 years old were excluded from this study to minimize the influence of age on the basal sex hormonal levels including testosterone. Forty of the forty-eight Brugada males have been included in our previous clinical studies.^{18–20} In all patients, physical examination, chest roentgenogram, laboratory values, echocardiography with wall motion analysis, and Doppler screening excluded structural heart diseases. The clinical, electrocardiographic, and electrophysiologic characteristics of the 48 Brugada males are shown in Table 1. Average age of the 48 Brugada males at diagnosis was 47 ± 12 years old. Aborted cardiac arrest or VF was documented in 21 males (44%), syncope alone in 11 males (23%), and 16 males (33%) were asymptomatic. Family history of sudden cardiac death (SCD) was observed in eight males (17%). An *SCN5A* coding region mutation was identified in seven (17%) of 42 males in whom genetic screening was conducted. Implantable cardioverter defibrillator (ICD) was implanted in all 32 symptomatic males with documented VF and/or syncope. ICD was also implanted in nine of 16 asymptomatic males due to induction of VF during the electrophysiologic study. Type 1 ST-segment elevation was recorded spontaneously in

43 males (90%) and was induced by sodium channel blockers in five males (10%). Complete right bundle branch block was observed in three males (6%). Late potential was recorded by a signal-average ECG system in 27 (59%) of 46 males. During the electrophysiologic study, VF requiring direct cardioversion for termination was induced in 32 (73%) of 44 males. Average HV interval was 46 ± 11 msec.

We first obtained data, such as the hormonal levels, visceral fat parameters, and ECG parameters in the 48 Brugada males prospectively between January and July in 2003, mainly at regular outpatient clinics for checking ICD. Only a Brugada male refused to participate during the recruitment of the case.

Thereafter, age-matched control males were randomly selected from the municipal population registry in Suita City. The hormonal and visceral fat data were collected sequentially between August and December in 2003. The municipal population registry in Suita City included 5,846 control subjects, among whom 1,052 males were age-matched to the 48 Brugada males. The 96 control males with a mean age of 50 ± 11 years were sequentially recruited from the age-matched 1,052 males. None of the recruited 96 control males refused to participate in this study. There were no significant differences in the clinical characteristics between the 96 control males and the remaining 956 age-matched males. Therefore, we had no way of knowing the body weight of the individuals who were selected to serve as controls from a very large database. Although K. Matsuo is a co-author of this study, none of the Brugada males and control males who appeared in the article by Matsuo¹⁶ are included in the present study population.

All protocols were approved by the Ethical Review Committee in the National Cardiovascular Center. Written informed consent was obtained from all subjects.

Sex and Thyroid Hormonal Levels and Serum Electrolytes

Blood samples for analysis of basal hormone levels and serum electrolytes were obtained between 8:00 and 9:00 AM after an overnight fast. Plasma sex hormonal levels including testosterone, estradiol, DHEA-S, LH, and FSH were measured using commercially prepared immunoassay kits (testosterone, LH, and FSH: Chemiluminescent immunoassay [Bayer HealthCare, New York, NY, USA]; estradiol: Electrochemiluminescent immunoassay [Roche Diagnostics GmbH, Mannheim, Germany]; DHEA-S: Radioimmunoassay [Diagnostic Products Corporation, Los Angeles, CA, USA]). Thyroid hormonal levels including free T3, T4, and TSH, and serum electrolyte levels including sodium, potassium, and chloride were also measured.

Body Mass Index and Body Fat Percentage

Body weight (BW) was measured to the nearest 0.1 kg and height to the nearest cm. Body-mass index (BMI) was calculated as $\text{weight}/\text{height}^2$ (kg/m^2) as a parameter of visceral fat. We also measured body-fat percentage (BF%) by using body composition analyzer (Biospace Co., Ltd. Tokyo, Japan). These visceral fat parameters were measured just after blood sampling. In the 32 symptomatic Brugada males who had had documented VF and/or syncope, the BW and BMI were also measured within 48 hours after their clinical events during admission in our hospital or other emergent hospitals.

TABLE 1

Clinical, Electrocardiographic, and Electrophysiologic Characteristics in the 48 Brugada Males

Clinical characteristics	
Age at diagnosis (years)	47 \pm 12
Aborted cardiac arrest or VF (%)	21/48 (44%)
Syncope alone (%)	11/48 (23%)
Asymptomatic (%)	16/48 (33%)
Family history of SCD	8/48 (17%)
<i>SCN5A</i> mutation	7/42 (17%)
ICD implantation	41/48 (85%)
Follow-up period (month)	41 \pm 2
Arrhythmic event (%)	9/48 (19%)
Electrocardiographic characteristics	
Spontaneous coved-type ST elevation	43/48 (90%)
CRBBB (%)	3/48 (6%)
RR (msec)	939 \pm 113
PQ interval (II) (msec)	186 \pm 34
QRS duration (V2) (msec)	104 \pm 18
Corrected QT interval (V5) (msec)	394 \pm 27
ST amplitude at J point (V2) (mV)	0.32 \pm 0.16
Late potential (%)	27/46 (59%)
Electrophysiologic characteristics	
Induction of VF	32/44 (73%)
Mode (Triple/Double/Single)	16/15/1
HV interval (msec)	46 \pm 11

CRBBB = complete right bundle branch block; ICD = implantable cardioverter defibrillator; SCD = sudden cardiac death; VF = ventricular fibrillation.

ECG Parameters

In the 48 males with Brugada syndrome, 12-lead ECG was recorded just before blood sampling, and ECG parameters were assessed by an investigator (WS) blinded to clinical information. The ECG parameters included RR interval, PQ interval measured in lead II, QRS interval measured in lead V2, QT interval, corrected QT (QTc) interval measured in leads V5, and ST amplitude at J point measured in lead V2.

Statistical Analysis

We first conducted univariate analysis by using unpaired *t*-test to compare each data between the Brugada males and the control males. Since several confounding variables, such as age, exercise (none, sometimes, regularly), stress (none, sometimes, regularly), current smoking (no, yes), and medication (no, yes) of hypertension, diabetes, and hyperlipidemia may affect the hormonal levels including testosterone level and the visceral fat parameters, analysis of covariance (ANCOVA) was used to compare least square mean values between the Brugada males and the control males adjusting for these confounding variables. Pearson's correlation coefficients were calculated between the testosterone level and the visceral fat parameters. Partial correlation coefficients were calculated between the testosterone level and the visceral fat parameters after adjusting for age, exercise, stress, current smoking, and medication. Moreover, conditional logistic regression models were used to calculate odds ratios and 95% confidence intervals adjusting for age, BMI, exercise, stress, current smoking, hypertension, diabetes, and hyperlipidemia. Hypertestosteronemia was defined as serum testosterone levels ≥ 700 ng/dL, which is 75 percentiles of testosterone levels among case and control combined groups. In the 32 Brugada males with documented VF and/or syncope, a paired *t*-test was used to compare the visceral fat parameters at the clinical

cardiac events and at the measurement of hormonal and visceral fat data. A two-sided *P* value below 0.05 was considered to indicate significance. All statistical analyses were performed by using SAS software, Ver 8.2.

Results

Hormonal Levels, Serum Electrolytes, and Visceral Fat

Table 2 illustrates univariate analysis for comparing sex and thyroid hormonal levels, serum electrolytes, and visceral fat parameters between the two groups. Testosterone level was significantly higher in the Brugada males than in the control males, whereas there were no significant differences in other sex hormonal levels; estradiol, DHEA-S, LH, FSH, and thyroid hormonal levels; T3, T4, and TSH. Serum sodium, potassium, and chloride levels were all significantly higher in the Brugada males than in the control males. BMI, BF%, and BW were all significantly lower in the Brugada males than in the control males. All variables followed normal distribution, both in the 48 Brugada and 96 control males.

The comparison of the confounding variables that may affect the hormonal levels and the visceral fat parameters between the 48 Brugada males and the 96 control males was shown in Table 3. Even after adjusting for age, exercise, stress, current smoking, and medication (hypertension, diabetes, and hyperlipidemia), the testosterone level, serum sodium, potassium, and chloride levels were all significantly higher, and the visceral fat parameters were significantly lower in the 48 Brugada males than in the 96 control males (Table 4). There were also significant differences in these parameters between the 24 definite Brugada males with documented VF and/or *SCN5A* mutations and the 96 control males after adjusting for the confounding variables (Table 4).

Correlation between Testosterone, Visceral Fat, and Serum Electrolytes

Testosterone level was inversely correlated with all visceral fat parameters, BMI, BF%, or BW in both the Brugada males and the control males, even after adjusting for age,

TABLE 2

Sex and Thyroid Hormonal Levels, Serum Electrolytes, and Visceral Fat Parameters in the 48 Brugada Males and the 96 Age-Matched Control Males

	Brugada Males (n = 48)	Control Males (n = 96)	P Value
Sex hormones			
Testosterone (ng/dL)	631 ± 176	537 ± 158	0.002
Estradiol (pg/mL)	28.9 ± 7.6	31.1 ± 12.6	0.263
DHEA-S (ng/mL)	1,901 ± 850	1,966 ± 861	0.668
LH (mIU/mL)	4.6 ± 2.6	3.9 ± 2.0	0.073
FSH (mIU/mL)	6.2 ± 4.9	5.0 ± 2.9	0.066
Thyroid hormones			
Free T3 (pg/mL)	3.3 ± 0.4	3.4 ± 0.3	0.360
Free T4 (ng/dL)	1.3 ± 0.1	1.3 ± 0.2	0.089
TSH (μ IU/mL)	1.9 ± 1.4	1.7 ± 1.4	0.619
Serum electrolytes			
Sodium (mEq/L)	143.7 ± 2.0	142.6 ± 2.0	0.003
Potassium (mEq/L)	4.6 ± 0.3	4.3 ± 0.3	<0.001
Chloride (mEq/L)	105.1 ± 2.1	103.6 ± 2.1	<0.001
Visceral fat			
BMI (kg/m ²)	22.1 ± 2.9	24.6 ± 2.6	<0.001
BF% (%)	19.6 ± 4.9	23.1 ± 4.7	<0.001
BW (kg)	62.9 ± 9.7	70.0 ± 8.6	<0.001

Values are mean \pm SD where indicated.

BMI = body-mass index; BF% = body-fat percentage; BW = body weight.

TABLE 3

Comparison of the Confounding Variables Between the 48 Brugada Males and the 96 Age-Matched Control Males

	Brugada Males (n = 48)	Control Males (n = 96)	P Value
Exercise			
None (%)	39.6	44.8	0.482
Sometimes (%)	41.6	43.8	
Regularly (%)	18.8	11.5	
Stress			
None (%)	27.1	21.9	0.684
Sometimes (%)	54.2	54.2	
Regularly (%)	18.8	24.0	
Current smoking (%)			
Medication	25.0	27.1	0.789
Hypertension (%)	20.8	19.8	0.883
Diabetes (%)	2.1	13.5	0.028
Hyperlipidemia (%)	10.4	5.2	0.246

TABLE 4

Testosterone, Serum Electrolytes, and Visceral Fat Parameters in the Brugada Males and the 96 Age-Matched Control Males after Adjusting for Confounding Variables

	Brugada Males	Control Males (n = 96)	P Value
ALL Case (n = 48)			
Testosterone (ng/dL)	631 ± 44	538 ± 40	0.003
Sodium (mEq/L)	144.2 ± 0.5	143.2 ± 0.5	0.007
Potassium (mEq/L)	4.6 ± 0.1	4.3 ± 0.1	<0.001
Chloride (mEq/L)	105.5 ± 0.5	103.9 ± 0.5	<0.001
BMI (kg/m ²)	22.3 ± 0.7	24.9 ± 0.7	<0.001
BF% (%)	20.0 ± 1.3	23.9 ± 1.1	<0.001
BW (kg)	63.4 ± 2.4	70.1 ± 2.1	0.001
Definite Brugada case with VF and/or SCNSA (n = 24)			
Testosterone (ng/dL)	656 ± 59	550 ± 48	0.009
Sodium (mEq/L)	143.9 ± 0.7	142.9 ± 0.6	0.042
Potassium (mEq/L)	4.7 ± 0.1	4.4 ± 0.1	<0.001
Chloride (mEq/L)	105.2 ± 0.7	103.9 ± 0.6	0.006
BMI (kg/m ²)	21.5 ± 1.0	24.5 ± 0.8	<0.001
BF% (%)	19.9 ± 1.7	24.1 ± 1.4	<0.001
BW (kg)	60.5 ± 3.1	69.2 ± 2.5	0.001

Values are mean ± SE adjusted for age, exercise, stress, current smoking, and medication of hypertension, diabetes and hyperlipidemia. BMI = body-mass index; BF% = body-fat percentage; BW = body weight; VF = ventricular fibrillation.

exercise, stress, current smoking, and medication (Brugada: BMI, $r = -0.394$, $P = 0.011$; BF%, $r = -0.390$, $P = 0.012$; BW, $r = -0.335$, $P = 0.032$; Control: BMI, $r = -0.333$, $p = 0.002$; BF%, $r = -0.333$, $P = 0.001$; BW, $r = -0.305$, $P = 0.004$), suggesting that Brugada males had higher testosterone level associated with lower visceral fat compared with control males (Fig. 1). No significant correlations were observed between other serum electrolytes and testosterone level or visceral fat parameters. Testosterone level was not correlated with age, even after adjusting for exercise, stress, current smoking, and medication ($r = 0.007$, $P = 0.947$).

Conditional Logistic Regression Models Analysis

Conditional logistic regression models analysis showed significant positive and inverse association between Brugada syndrome, hypertestosteronemia (Odd Ratio (OR): 3.11, 95%CI: 1.22–7.93, $P = 0.017$), and BMI (OR: 0.72, 95%CI: 0.61–0.85, $P < 0.001$), respectively (Table 5). Other variables did not significantly increase or decrease risks of Brugada syndrome (Table 5).

Visceral Fat at Clinical Cardiac Events in Brugada Males

In the 32 symptomatic Brugada males with documented VF and/or syncope, the time-span between the clinical cardiac events and the measurement of hormonal and the visceral fat data was 42 ± 32 months (mean ± SD, 1–99 months). The BMI and BW at the clinical cardiac events (VF or syncope) were significantly lower than those at the measurement of hormonal and visceral fat data (BMI, 21.0 ± 2.6 vs 22.1 ± 2.9 kg/m²; BW, 60.0 ± 8.9 vs 62.9 ± 9.7 kg; $P < 0.001$, respectively).

Testosterone versus ECG Parameters, Symptoms or SCNSA Mutation in Brugada Males

Baseline electrocardiographic data of the 48 Brugada males are shown in Table 1. No significant correlations were observed between testosterone level and ECG parameters, including ST amplitude ($r = -0.123$, $P = 0.406$) and QTc interval ($r = -0.206$, $P = 0.160$), in the 48 Brugada males. There was no significant difference in testosterone level between 32 symptomatic and 16 asymptomatic Brugada males (649 ± 185 vs 593 ± 157 ng/dL; $P = 0.298$). No significant difference was observed in testosterone level between 43 Brugada males with spontaneous Type 1 ST-segment elevation and five Brugada males with sodium channel blocker-induced Type 1 ST-segment elevation (624 ± 171 vs 688 ± 230 ng/dL; $P = 0.448$). Testosterone level was also no different between seven Brugada males with SCNSA mutation and 41 Brugada males without SCNSA mutation (700 ± 198 vs 619 ± 172 ng/dL; $P = 0.261$).

Follow-Up

Arrhythmic events occurred in nine (19%) of 48 Brugada males during average follow-up periods of 41 ± 2 months after blood sampling for the present study (Table 1). In more detail, arrhythmic events appeared in eight (38%) of 21 Brugada males with a history of aborted cardiac arrest or VF, in one (9%) of 11 Brugada males with syncope alone, but did not appear in any (0%) of 16 asymptomatic Brugada males.

Discussion

The major findings of the present study were: (1) Brugada males had significantly higher testosterone level, serum sodium, potassium, and chloride level, and significantly lower BMI, BF%, and BW than those in control males by univariate analysis, even after adjusting for age, exercise, stress, current smoking, and medications related to hypertension, diabetes and hyperlipidemia. (2) Testosterone level was inversely correlated with the BMI, BF%, and BW in both Brugada males and control males, even after adjusting for the confounding variables. (3) Conditional logistic regression models analysis showed strong positive association between Brugada syndrome and higher testosterone level (hypertestosteronemia) and strong inverse association between Brugada syndrome and BMI.

Testosterone in Brugada Phenotype and Male Predominance

For the past decade, numerous clinical, experimental, and molecular genetic studies have elucidated Brugada syndrome as a distinct clinical entity.^{1–5,17} However, several problems remain unresolved, such as genetic heterogeneity, ethnic difference, and gender difference.⁷ Di Diego and Antzelevitch recently suggested the cellular basis for male predominance in Brugada syndrome by using arterially perfused canine right ventricular wedge preparations.⁹ Transient outward current (I_{to})-mediated phase 1 AP notch was larger in male dogs than in female dogs in the right ventricular epicardium, but not in the left ventricular epicardium, responsible for the male predominance in the Brugada phenotype. Recent clinical studies suggested that male hormone testosterone might be attributable to gender difference of the prevalence in this




Figure 1. Correlation between testosterone level and visceral fat parameters; body mass index (BMI) (A and B), body fat percentage (BF%) (C and D), and body weight (BW) (E and F) in the 48 Brugada males and the 96 age-matched control males. Testosterone level was inversely correlated with the BMI, BF%, or BW in both Brugada males and control males.

syndrome. Matsuo et al. reported two cases of asymptomatic Brugada syndrome in whom typical coved ST-segment elevation disappeared following orchiectomy as therapy for prostate cancer,²¹ indicating that testosterone may contribute to the Brugada phenotype in these two cases. Several experimental studies reported that testosterone increased outward potassium currents, such as the rapidly activating component (I_{Kr}),^{10,11} and the slowly activating component (I_{Ks})¹² of the delayed rectifier potassium current, and the inward rectifier potassium current (I_{K1}),¹¹ or decreased inward L-type calcium current (I_{Ca-L}).¹² Since the maintenance of the AP dome is determined by the fine balance of currents active at the end of phase 1 of the AP (principally I_{to} and I_{Ca-L}),^{22,23} any agents that increase outward currents or decrease inward currents can increase the magnitude of the AP notch, leading

to loss of the AP dome (all-or-none repolarization) in the epicardium, but not in the endocardium, contributing to a significant voltage gradient across the ventricular wall during ventricular activation; thus augmenting ST-segment elevation, the Brugada phenotype.²⁴ Therefore, testosterone would be expected to accentuate the Brugada phenotype. In the present study, males with Brugada syndrome had significantly higher testosterone level than age-matched control males, even after adjusting for age, exercise, stress, current smoking, and medication (hypertension, diabetes, and hyperlipidemia), which may affect the testosterone level. Moreover, conditional logistic regression models analysis showed strong positive association between Brugada syndrome and higher testosterone level (OR: 3.11). Our data suggest a significant role of testosterone, male hormone, in the Brugada phenotype. The

TABLE 5

Odds Ratios of Presence of Hypertestosteronemia and Confounding Risk Factors for Brugada Syndrome in Males

Variable	Odd Ratio	95% Confidence		P Value
		Interval		
Hypertestosteronemia	3.11	1.22–7.93	0.017	
Age	0.99	0.95–1.03	0.637	
BMI	0.72	0.61–0.85	<0.001	
Exercise	1.57	0.87–2.83	0.135	
Stress	0.69	0.35–1.35	0.277	
Current smoking	0.71	0.26–1.90	0.493	
Hypertension	3.12	0.85–11.45	0.087	
Diabetes	0.13	0.01–1.27	0.079	
Hyperlipidemia	2.14	0.44–10.49	0.348	

Hypertestosteronemia was defined as serum testosterone levels ≥ 700 ng/dL.

data also indicate that the male predominance in the Brugada phenotype is at least in part due to testosterone, which is present only in males.

Lower Visceral Fat May Be a Predictor for Brugada Phenotype

Matsuo et al. recently reported in their epidemiologic study that cases with the Brugada-type ECG had significantly lower BMI than that in control subjects.¹⁶ Similarly, in the present study, males with Brugada syndrome had significantly lower visceral fat parameters, BMI, BF%, and BW than those in age-matched control males, even after adjusting for several confounding variables. Moreover, conditional logistic regression models analysis showed strong inverse association between Brugada syndrome and BMI (OR: 0.72). All of the visceral fat parameters were inversely correlated with testosterone level in both Brugada and control males, even after adjusting for the confounding variables. It has been well demonstrated that testosterone level in obese males is decreased compared to normal males of similar age.¹³ Tsai et al. reported that lower baseline total testosterone level independently predicted an increase in visceral fat in the Japanese-American male cohort for 7.5 years.¹⁵ Conversely, Marin et al. reported that testosterone treatment of middle-aged abdominally obese males was followed by a decrease of visceral fat mass measured by computerized tomography.¹⁴ These data suggest that primarily higher level of testosterone in Brugada males compared to that in control males may result in lower visceral fat in Brugada males, which would be an "innocent bystander" sign of Brugada phenotype. In reverse, if primary lower visceral fat (body weight loss) would result in higher testosterone level, the weight loss could be a trigger for Brugada phenotype, just like fever is.²⁵ It is noteworthy that the visceral fat parameters at the clinical cardiac events (VF or syncope) in the 32 symptomatic Brugada males were significantly lower than those at the time of blood sampling for this study. This indicates that testosterone level is expected to be additively higher at the clinical cardiac events, which may contribute to spontaneous episodes of VF or syncope.

Other Hormonal Levels and Serum Electrolytes

Estradiol, female hormone, is reported to reduce the expression of Kv4.3 channels, which are important molecular

components of I_{to} currents.²⁶ However, in contrast to testosterone, other sex hormonal levels including estradiol were not different between the Brugada males and the control males in the present study. Although thyroid hormones are also demonstrated to alter membrane currents, such as I_{to} and I_{Ca-L} ,^{27,28} no significant differences were observed in the thyroid hormonal levels between the two groups in the present study.

On the other hand, serum sodium, potassium, and chloride levels were all significantly higher in the Brugada males than in the control males, even after adjusting for several confounding variables. Recently, many agents and conditions that cause an outward shift in current activity at the end of phase 1 AP have been known to unmask ST-segment elevation, as found in the Brugada syndrome, leading to the acquired form of this disorder.^{4,29} Electrolyte abnormalities, such as hyperkalemia, are reported to amplify ST-segment elevation like that in Brugada syndrome.³⁰ The lower visceral fat found in the Brugada males is expected to decrease serum level of insulin, leptine, a novel adipocyte-derived hormone, or ghrelin, a novel growth hormone-releasing peptide, suppressing β -adrenergic receptor or plasma norepinephrine level, resulting in an increase of serum potassium level.^{31,32} Further studies including measurement of levels of insulin, leptine, and ghrelin will be required to elucidate the precise mechanism.

Study Limitations

Although the testosterone level was significantly higher in the Brugada males than in the control males, no statistically significant correlations were observed between the testosterone level and the ST amplitude in the Brugada males. The degree of the ST-segment elevation is variable between Brugada patients because it is influenced by several factors other than sex hormonal levels or electrolytes levels, such as basal autonomic tone, presence of *SCN5A* mutation, or probably intrinsic current density of I_{to} , etc., in the right ventricular epicardial cells. The threshold of ST-segment elevation for spontaneous induction of VF also varies between Brugada patients. Therefore, the Brugada phenotype, such as ST-segment elevation or spontaneous induction of VF, may correlate with the testosterone level day to day individually (intra-personally) in each Brugada male, but may not correlate among the pooled data obtained from many Brugada males, probably due to inter-person difference of the ST-segment elevation.

There were no significant differences in testosterone level between symptomatic and asymptomatic Brugada males, between Brugada males with spontaneous ST elevation and those with sodium channel blocker-induced ST elevation, or between Brugada males with and without *SCN5A* mutation, all of which are probably due to a relatively small number of Brugada males in the present study. Further evaluation with increasing number of Brugada males will be required.

Acknowledgment: We gratefully acknowledge the helpful suggestions of Yoshihiro Miyamoto, Laboratory of Molecular Genetics, National Cardiovascular Center, Suita, Japan.

References

1. Brugada P, Brugada J: Right bundle branch block, persistent ST segment elevation and sudden cardiac death: A distinct clinical and

- electrocardiographic syndrome: A multicenter report. *J Am Coll Cardiol* 1992;20:1391-1396.
2. Brugada J, Brugada R, Brugada P: Determinants of sudden cardiac death in individuals with the electrocardiographic pattern of Brugada syndrome and no previous cardiac arrest. *Circulation* 2003;108:3092-3096.
 3. Priori SG, Napolitano C, Gasparini M, Pappone C, Della Bella P, Giordano U, Bloise R, Giustetto C, De Nardis R, Grillo M, Ronchetti E, Faggiano G, Nastoli J: Natural history of Brugada syndrome: Insights for risk stratification and management. *Circulation* 2002;105:1342-1347.
 4. Antzelevitch C, Brugada P, Borggreffe M, Brugada J, Brugada R, Corrado D, Gussak I, Lemarec H, Nademanee K, Perez Riera AR, Shimizu W, Schulze-Bahr E, Tan H, Wilde A: Brugada syndrome. Report of the second consensus conference. Endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. *Circulation* 2005;111:659-670.
 5. Eckardt L, Probst V, Smits JP, Bahr ES, Wolpert C, Schimpf R, Wichter T, Boisseau P, Heinecke A, Breithardt G, Borggreffe M, Lemarec H, Bocker D, Wilde AA: Long-term prognosis of individuals with right precordial ST-segment-elevation brugada syndrome. *Circulation* 2005;111:257-263.
 6. Chen Q, Kirsch GE, Zhang D, Brugada R, Brugada J, Brugada P, Potenza D, Moya A, Borggreffe M, Breithardt G, Ortiz-Lopez R, Wang Z, Antzelevitch C, O'Brien RE, Schulze-Bahr E, Keating MT, Towbin JA, Wang Q: Genetic basis and molecular mechanisms for idiopathic ventricular fibrillation. *Nature* 1998;392:293-296.
 7. Shimizu W, Aiba T, Kamakura S: Mechanisms of disease: Current understanding and future challenges in Brugada syndrome. *Nat Clin Pract Cardiovasc Med* 2005;2:408-414.
 8. Shimizu W: Editorial comment, gender difference and drug challenge in Brugada syndrome. *J Cardiovasc Electrophysiol* 2004;15:70-71.
 9. Di Diego JM, Cordeiro JM, Goodrow RJ, Fish JM, Zygmunt AC, Perez GJ, Scornik FS, Antzelevitch C: Ionic and cellular basis for the predominance of the Brugada syndrome phenotype in males. *Circulation* 2002;106:2004-2011.
 10. Shuba YM, Degtiar VE, Osipenko VN, Naidenov VG, Woosley RL: Testosterone-mediated modulation of HERG blockade by proarrhythmic agents. *Biochem Pharmacol* 2001;62:41-49.
 11. Liu XK, Katchman A, Whitfield BH, Wan G, Janowski EM, Woosley RL, Ebert SN: In vivo androgen treatment shortens the QT interval and increases the densities of inward and delayed rectifier potassium currents in orchietomized male rabbits. *Cardiovasc Res* 2003;57:28-36.
 12. Bai CX, Kurokawa J, Tamagawa M, Nakaya H, Furukawa T: Non-transcriptional regulation of cardiac repolarization currents by testosterone. *Circulation* 2005;112:1701-1710.
 13. Glass AR, Swerdloff RS, Bray GA, Dahms WT, Atkinson RL: Low serum testosterone and sex-hormone-binding-globulin in massively obese men. *J Clin Endocrinol Metab* 1977;45:1211-1219.
 14. Marin P, Holmang S, Jonsson L, Sjostrom L, Kvist H, Holm G, Lindstedt G, Bjorntorp P: The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. *Int J Obes Relat Metab Disord* 1992;16:991-997.
 15. Tsai EC, Boyko EJ, Leonetti DL, Fujimoto WY: Low serum testosterone level as a predictor of increased visceral fat in Japanese-American men. *Int J Obes Relat Metab Disord* 2000;24:485-491.
 16. Matsuo K, Akahoshi M, Nakashima E, Seto S, Yano K: Clinical characteristics of subjects with the Brugada-type electrocardiogram: A case control study. *J Cardiovasc Electrophysiol* 2004;15:653-657.
 17. Wilde AA, Antzelevitch C, Borggreffe M, Brugada J, Brugada R, Brugada P, Corrado D, Hauer RN, Kass RS, Nademanee K, Priori SG, Towbin JA: Study group on the molecular basis of arrhythmias of the European Society of Cardiology. Proposed diagnostic criteria for the Brugada syndrome: Consensus report. *Circulation* 2002;106:2514-2519.
 18. Shimizu W, Matsuo K, Takagi M, Tanabe Y, Aiba T, Taguchi A, Suyama K, Kurita T, Aihara N, Kamakura S: Body surface distribution and response to drugs of ST segment elevation in the Brugada syndrome: Clinical implication of 87-leads body surface potential mapping and its application to 12-leads electrocardiograms. *J Cardiovasc Electrophysiol* 2000;11:396-404.
 19. Kanda M, Shimizu W, Matsuo K, Nagaya N, Taguchi A, Suyama K, Kurita T, Aihara N, Kamakura S: Electrophysiologic characteristics and implication of induced ventricular fibrillation in symptomatic patients with Brugada syndrome. *J Am Coll Cardiol* 2002;39:1799-1805.
 20. Yokokawa M, Takaki H, Noda T, Satomi K, Suyama K, Kurita T, Kamakura S, Shimizu W: Spatial distribution of repolarization and depolarization abnormalities evaluated by body surface potential mapping in patients with Brugada syndrome. *Pacing Clin Electrophysiol* 2006;29:1112-1121.
 21. Matsuo K, Akahoshi M, Seto S, Yano K: Disappearance of the Brugada-type electrocardiogram after surgical castration: A role for testosterone and an explanation for the male preponderance. *Pacing Clin Electrophysiol* 2003;26:1551-1553.
 22. Litovsky SH, Antzelevitch C: Transient outward current prominent in canine ventricular epicardium but not endocardium. *Circ Res* 1988;62:116-126.
 23. Furukawa T, Myerburg RJ, Furukawa N, Bassett AL, Kimura S: Differences in transient outward currents of feline endocardial and epicardial myocytes. *Circ Res* 1990;67:1287-1291.
 24. Yan GX, Antzelevitch C: Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST segment elevation. *Circulation* 1999;100:1660-1666.
 25. Mok NS, Priori SG, Napolitano C, Chan NY, Chahine M, Baroudi G: A newly characterized SCN5A mutation underlying Brugada syndrome unmasked by hyperthermia. *J Cardiovasc Electrophysiol* 2003;14:407-411.
 26. Song M, Helguera G, Eghbali M, Zhu N, Zarei MM, Olcese R, Toro L, Stefani E: Remodeling of Kv4.3 potassium channel gene expression under the control of sex hormones. *J Biol Chem* 2001;276:31883-31890.
 27. Wickenden AD, Kaprielian R, You XM, Backx PH: The thyroid hormone analog DITPA restores I(to) in rats after myocardial infarction. *Am J Physiol Heart Circ Physiol* 2000;278:H1105-H1116.
 28. Sunagawa M, Yamakawa M, Shimabukuro M, Higa N, Takasu N, Kotsugi T: Electrophysiologic characteristics of atrial myocytes in levothyroxine-treated rats. *Thyroid* 2005;15:3-11.
 29. Shimizu W: Acquired forms of Brugada syndrome (Antzelevitch C review). In: *The Brugada Syndrome: From Bench to Bedside*, Chapter 14. Blackwell Futura, UK, 2004;166-177.
 30. Myers GB: Other QRS-T patterns that may be mistaken for myocardial infarction. IV. Alterations in blood potassium; myocardial ischemia; subepicardial myocarditis; distortion associated with arrhythmias. *Circulation* 1950;2:75-93.
 31. Collins S, Kuhn CM, Petro AE, Swick AG, Chrnyk BA, Surwit RS: Role of leptin in fat regulation. *Nature* 1996;380:677.
 32. Nagaya N, Moriya J, Yasumura Y, Uematsu M, Ono F, Shimizu W, Ueno K, Kitakaze M, Miyatake K, Kangawa K: Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. *Circulation* 2004;110:3674-3679.

Characterization of Subclinical Thyroid Dysfunction From Cardiovascular and Metabolic Viewpoints

— The Suita Study —

Naoyuki Takashima, MD; Yasuharu Niwa, PhD; Toshifumi Mannami, MD*;**;
Hitonobu Tomoike, MD*; Naoharu Iwai, MD

Background Subclinical hypothyroidism, defined as high serum thyroid-stimulating hormone (TSH) levels and normal serum free-triiodothyronine (fT3) and serum free-thyroxine (fT4) levels, is a common medical problem among the elderly, but it is unclear whether it should be treated with thyroid hormone replacement therapy.

Methods and Results A cross-sectional study of 3,607 participants in a community health survey in Suita, in the northern part of Osaka, was performed. Participants were categorized into 5 groups: normal, hyperthyroidism, hypothyroidism, subclinical hypothyroidism, and subclinical hyperthyroidism. The association between each group and various phenotypes was examined, in relation to cardiovascular disease and metabolic syndromes. Serum TSH levels increased and fT3 and fT4 levels decreased with age. A total of 14.6% of subjects aged 70–80 years and 20.1% of subjects aged older than 80 years were classified as having subclinical hypothyroidism. Subclinical hypothyroidism was not associated with glycol-hemoglobin A1c, body mass index, pulse rate, hypertension, total cholesterol, high-density lipoprotein cholesterol or triglyceride levels or intima-media thickness. It was only associated with higher fasting blood glucose and glycol-hemoglobin A1c levels compared with euthyroidism.

Conclusions The present observation does not support the need for treatment of subclinical hypothyroidism or subclinical hyperthyroidism. (*Circ J* 2007; 71: 191–195)

Key Words: Blood sugar; Diabetes; Lipids; Subclinical hyperthyroidism; Subclinical hypothyroidism

Subclinical hypothyroidism (SCH), defined as high serum thyroid-stimulating hormone (TSH) levels and normal levels of serum free-triiodothyronine (fT3) and serum free-thyroxine (fT4), is a common medical problem among the elderly. The prevalence of SCH has been reported to be 4–10% in the general population and up to 20% in women older than 60 years!^{1–3} The incidence of SCH is 2.1–3.8% per year in thyroid-antibody-positive subjects and 0.3% per year in thyroid-antibody-negative subjects⁴

Serum lipid levels in SCH have been reported as either normal⁵ or elevated.^{6,7} In the Tromsø study, low-density lipoprotein-cholesterol (LDL-C) levels were significantly higher in subjects with SCH compared with controls⁷ and, moreover, they were reduced with thyroxine treatment. In addition, associations between left ventricular function and SCH have been widely investigated, but the findings are controversial. Some studies have shown an association between SCH and poor left ventricular function and others have not.⁸ Moreover, the positive association between arterial stiffness and hypothyroidism, even in the subclinical stage, has been reported.^{9,10} Subclinical hyperthyroidism has been associated with a higher prevalence of atrial fibrillation (AF) and increased heart rate,⁸ but not with elevated serum lipid levels.⁶

In the present study we investigated whether subclinical thyroid dysfunction in Japanese individuals is associated with various phenotypes related to cardiovascular disease and metabolic syndromes.

Methods

Study Population

The selection criteria and design of the Suita study have been described previously!^{11–13} Serum TSH, fT3, and fT4 levels were measured in 3,607 subjects who were not being treated for thyroid disease. The present study was approved by the Ethics Committee of the National Cardiovascular Center, and all subjects provided written informed consent. We categorized patients into 5 groups: normal (normal levels of serum TSH [0.436–3.78 μU/ml], fT3 [2.1–4.1 pg/ml] and fT4 [1.0–1.7 ng/dl]), hyperthyroidism (low levels of TSH and high levels of fT3 and/or fT4), hypothyroidism (high levels of TSH and low levels of fT3 and/or fT4), SCH (high levels of TSH and normal levels of fT3 and fT4), and subclinical hyperthyroidism (low levels of TSH and normal levels of fT3 and fT4).¹⁴ Body mass index (BMI) was calculated as body weight (kg) divided by height in square meters.

The intima-media thickness (IMT) was measured on longitudinal scan of the common carotid artery at a point 10 mm proximal from the beginning of the dilation of the bulb!¹¹

Serum TSH, fT3, and fT4 Levels

Fasting serum samples were collected at study entry and stored at –80°C until tests were run. Serum TSH was mea-

(Received August 17, 2006; revised manuscript received October 31, 2006; accepted November 20, 2006)

Departments of Epidemiology, *Preventive Cardiology, National Cardiovascular Center, Suita and **Hygiene and Public Health, Social Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan
Mailing address: Naoyuki Takashima, MD, Department of Epidemiology, National Cardiovascular Center, 5-7-1 Fujishirodai, Suita 565-8565, Japan. E-mail: ntaka@ri.ncvc.go.jp




Fig 1. Serum TSH, ft3, and ft4 hormone levels and age. (A–C) Correlation between serum TSH (A), ft3 (B), and ft4 levels (C) and age are plotted (grey dot). Serum TSH levels increased with age. There was a linear correlation between log transformed serum TSH levels and age. Serum ft3 and ft4 levels decreased with age. There was a linear correlation between these thyroid hormone levels and age ($p < 0.01$). (D–E) The prevalence of women (D) and men (E) in each thyroid state according to age is shown. The total number of subjects according to age is shown by the black line. The prevalence of subclinical hypothyroidism in both men and women increased with age. However the prevalence of subclinical hyperthyroidism did not increase with age. TSH thyroid-stimulating hormone; ft3, serum free-triiodothyronine; ft4 serum free-thyroxine.

sured by a chemiluminescent immunoassay kit (Mitsubishi Kagaku BCL, Abbott Laboratories, Chicago, IL, USA), as were serum ft3 and ft4 levels (Mitsubishi Kagaku BCL, Bayer, Leverkusen, Germany).

Statistical Analysis

Values are expressed as mean \pm standard deviation. All statistical analyses were performed with the JMP statistical package (SAS Institute Inc, Cary, NC, USA). One-way analysis of variance tests were used to determine whether an association existed among thyroid status and BMI (adjusted for age and sex), systolic and diastolic blood pressures (SBP: adjusted for age, BMI, and sex; DBP: adjusted for age, BMI, and sex), pulse rate (PR; adjusted for age and sex), glycol-hemoglobin A1c (HbA1c: adjusted for age, BMI, and sex), fasting blood glucose levels (FBG: adjusted for age, BMI, and sex), high-density lipoprotein (HDL: adjusted for cholesterol BMI, sex, age, number of cigarettes/day, and alcohol consumption [g/day]), total cholesterol (TC: adjusted for age, BMI, and sex), triglycerides (TG: adjusted for age, BMI, and sex) and IMT. Simple correlation analyses were used to determine whether an association existed between normal states and each thyroid state, as well as between the variables assessed after adjusting for confounding factors. Logistic analysis was used to determine whether an association existed among thyroid status and the prevalence of AF.

Results

Serum concentrations of TSH increased and serum concentrations of ft3 and ft4 decreased with age (Figs 1A–C). Similarly, the number of men and women with SCH also increased with age (Figs 1D,E). Overall, 11.6% of women aged 71–80 years and 13.8% of women aged older than 80 years were classified into the SCH category (Fig 1D). For men, 13.4% aged 71–80 years and 24.5% older than 80 years were classified into the SCH category (Fig 1E).

The characteristics of the study population are shown in Table 1. Participants included 3,130 normal subjects, 19 with hyperthyroidism, 4 with hypothyroidism, 77 with sub-

clinical hyperthyroidism, and 377 with SCH. The prevalence of SCH was 10.45% and that of subclinical hyperthyroidism was 2.13%. Compared with normal individuals, subjects with SCH were significantly older (69.02 ± 10.43 years vs 64.22 ± 11.29 years, respectively; $p < 0.05$) and had significantly lower serum ft3 levels (2.99 ± 0.33 ng/dl vs 3.12 ± 0.32 ng/dl, respectively; $p < 0.01$, adjusted for age and sex) and ft4 levels (1.09 ± 0.19 pg/ml vs 1.24 ± 0.15 pg/ml, respectively; $p < 0.01$, adjusted for age and sex). On the other hand, when individuals with subclinical hyperthyroidism were compared with normal subjects, they showed significantly higher concentrations of ft4 (1.34 ± 0.18 pg/ml vs 1.24 ± 0.15 pg/ml, respectively; $p < 0.01$, adjusted for age and sex). Subjects with overt hyperthyroidism had significantly lower HDL ($p < 0.01$) and TC levels ($p < 0.01$) and higher PR ($p < 0.01$) than subjects with normal thyroid function. Subjects with overt hypothyroidism had significantly higher TC levels ($p < 0.01$) than subjects with normal thyroid function. Characteristics associated with hyper- and hypothyroid subjects were as reported previously!⁵

Characteristics of subjects with normal and subclinical thyroid dysfunction are shown in Table 2. The PR among subjects not being treated for arrhythmia was not significantly associated with subclinical hyperthyroidism or SCH after adjusting for age and sex. Blood pressure among subjects not being treated for hypertension was not significantly associated with subclinical hyperthyroidism or SCH after adjusting for appropriate confounding factors. Among subjects not being treated for hypertriglyceridemia, TG levels were not significantly associated with subclinical hyperthyroidism or SCH compared with normal subjects. HDL-cholesterol and TC levels were not significantly associated with subclinical hyperthyroidism or SCH subjects not being treated for hyperlipidemia. Among all subjects not receiving treatment for diabetes, FBG was significantly associated with SCH ($p < 0.01$). Subjects with subclinical hyperthyroidism had significantly higher HbA1c ($p < 0.05$) and FBG ($p < 0.01$) levels than normal subjects. The numbers of subjects not being treated for each disease is shown in Table 2.

The prevalence of AF in subjects with subclinical hyper-

Table 1 Characteristics of the Study Population

	Normal thyroid	Hyperthyroidism	Hypothyroidism	Subclinical hyperthyroidism	Subclinical hypothyroidism	Total
N (%)	3,130 (86.78)	19 (0.53)	4 (0.11)	77 (2.13)	377 (10.45)	3,607 (100)
Male (%)	1,442 (46.07)	5 (26.32)	3 (75.0)	39 (50.65)	203 (53.85)	1,692 (44.55)
Age (years)	64.22±11.29	62.16±12.85	76.50±8.43	63.94±10.85	69.02±10.43 [‡]	64.70±11.29
BMI	22.82±3.11	22.73±3.48	24.02±0.58	22.77±3.03	22.84±3.34	22.82±3.14
SBP (mmHg)	129.24±19.65	131.32±20.63	135.50±10.47	125.57±15.45	131.93±19.06	129.41±19.69
DBP (mmHg)	77.82±10.09	76.11±11.95	71.50±15.37	75.03±10.76	77.97±9.61	77.74±10.17
PR (beats/min) [‡]	66.10±8.25	72.42±9.74 [‡]	62.00±3.27	67.12±9.38	66.51±8.35	66.20±8.38
FBG (mg/dl) [‡]	99.75±21.32	105.16±40.89	99.00±4.97	106.79±38.83 [‡]	98.64±18.68	99.79±21.67
HbA1c (%) [‡]	5.49±0.74	5.47±0.86	5.57±0.31	5.73±1.49 [‡]	5.54±0.77	5.50±0.77
HDL-C (mg/dl)	60.56±15.52	51.11±15.81 [‡]	55.25±16.80	58.71±17.01	58.47±16.01	60.20±15.61
TC (mg/dl)	208.26±32.09	185.58±35.83 [‡]	247.25±55.05 [‡]	206.79±33.26	206.34±35.48	207.99±32.53
TG (mg/dl)	106.90±74.77	111.74±64.30	156.00±61.36	123.12±72.03	113.30±69.72	108.16±74.59
Prevalence of MI (%)	40 (1.28)	0 (0.00)	0 (0.00)	2 (2.60)	7 (1.86)	49 (1.36)
Prevalence of CVA (%)	89 (2.84)	0 (0.00)	0 (0.00)	3 (3.90)	13 (3.45)	105 (2.91)
Prevalence of AF (%)	44 (1.41)	0 (0.00)	0 (0.00)	2 (2.60)	15 (3.98)	61 (1.69)
TSH (μU/ml)	1.723±0.824	0.10±0.20	209.85±171.57 [‡]	0.27±0.13*	8.32±11.42 [‡]	2.60±9.51
ft4 (ng/dl)	1.24±0.15	2.26±0.97 [‡]	0.35±0.0 [‡]	1.34±0.18 [‡]	1.09±0.19 [‡]	1.23±0.20
ft3 (pg/ml)	3.12±0.32	6.75±5.77 [‡]	1.65±0.29 [‡]	3.18±0.46	2.99±0.33 [‡]	3.12±0.59

[‡]p<0.05 and [‡]p<0.01.

P values are for comparisons with normal thyroid subjects after adjustment for appropriate confounding factors.

Values are mean ± standard deviation.

[‡]Number of patients treated for arrhythmia was 61 in normal subjects, 1 in subclinical hyperthyroidism subjects, and 9 in subclinical hypothyroidism subjects;

[‡]number of patients treated for diabetes was 150 in normal subjects, 1 in hyperthyroidism subjects, 7 in subclinical hyperthyroidism subjects, and 22 in subclinical hypothyroidism subjects.

BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; PR, pulse rate; FBG, fasting blood glucose levels; Hb, hemoglobin; HDL, high-density lipoprotein; C, cholesterol; TC, total cholesterol; TG, triglyceride; MI, myocardial infarction; CVA, cerebrovascular accident; AF, atrial fibrillation; TSH, thyroid-stimulating hormone; ft4, free-thyroxine; ft3, free-triiodothyronine.

Table 2 Characteristics of the Subjects in the Normal and Subclinical Thyroidism Groups

	Normal thyroid	Subclinical hyperthyroidism	Subclinical hypothyroidism	ANOVA p-value**
N	3,130	77	377	
BMI	22.82±3.11	22.77±3.03	22.84±3.34	NS
N [‡]	2,355	57	270	
SBP (mmHg)	124.95±18.37	122.53±20.00	127.74±17.98	NS
DBP (mmHg)	76.67±9.98	73.49±10.99	76.93±9.50	NS
N [‡]	3,057	75	364	
PR (beats/min)	66.12±8.23	67.33±9.40	66.47±8.27	NS
N [‡]	2,976	70	355	
HbA1c	5.40±0.56	5.56±1.34*	5.41±0.48	<0.05
FBG (mg/dl)	97.07±15.27	103.6±36.73 [‡]	95.58±11.57 [‡]	<0.0001
N ^{‡†}	3,084	73	371	
TG (mg/dl)	105.95±74.12	121.52±75.98	112.73±69.70	NS
N [‡]	2,726	63	320	
HDL (mg/dl)	60.58±15.65	58.40±17.36	58.37±16.41	NS
TC (mg/dl)	207.78±32.47	207.40±34.81	205.44±36.39	NS

*<0.05 and [‡]<0.01.

**P values are for comparisons with normal thyroid subjects after adjustment for appropriate confounding factors.

Values are mean ± standard deviation.

[‡]Without treatment for hypertension; [‡]without treatment for arrhythmia; [‡]without treatment for diabetes mellitus; ^{‡†}without treatment for hypertriglyceridemia; [‡]without treatment for hyperlipidemia.

ANOVA, analysis of variance. Other abbreviations see in Table 1.

thyroidism was higher than that in normal subjects (3.98% vs 1.41%) but the difference was not statistically significant. Subjects who had been diagnosed with AF were included with those with AF.

A total of 12% of subjects with SCH had high serum TSH levels (>10μU/ml). Subjects with SCH and TSH levels >10μU/ml were older than subjects with SCH and TSH levels =10μU/ml (67.28±9.62 years vs 71.07±9.70 years, p<0.05). Subjects with SCH and high TSH levels (>10μU/ml) did not have lower FBG, HbA1c or lipid levels compared with normal subjects (unpubl. data).

The correlation between laboratory data and ft3, ft4, and TSH levels in normal subjects is shown in Table 3. Serum ft4 and ft3 levels in normal subjects were significantly associated with various laboratory data after adjusting for appropriate confounding factors.

We examined whether an association between IMT and thyroid dysfunction existed (Table 4). There were weak associations between thyroid states and IMT-mean, and IMT-max, but these disappeared after adjusting for age and sex. Multiple logistic analysis did not detect a significant correlation between thyroid state (normal or subclinical